Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Total Current Assets
All assets expected to be converted to cash or used up within one year.
Profound Medical Corp.NASDAQ: PROF
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 16.4% from a year ago
Total current assets stood at $69.76M at the end of Q1 FY2026, up 16.4% from a year earlier and down 33.1% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.
Context
- Total current assets amounted to 94.7% of total assets at the end of Q1 FY2026, down 3.8 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +16.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 104.21M USD
- Year-over-year change
- +50.9%
- 4-year CAGR
- +7.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.21M | +50.9% |
| FY2024 | 2024-12-31 | 69.07M | +64.8% |
| FY2023 | 2023-12-31 | 41.9M | -32.5% |
| FY2022 | 2022-12-31 | 62.02M | -19.5% |
| FY2021 | 2021-12-31 | 77.02M | — |
Total Current Assets vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's Mar 2026 total current assets of $69.76M is the 6th highest of the 11 companies compared; the peer median is $75.3M.
- Its year-over-year change of +16.4% is the 6th highest of 11, against a peer median of +6.9%.
- Total current assets amounts to 94.7% of total assets for PROF, versus a peer median of 65.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AVRAnteris Technologies Global Corp. | Mar 2026 | $286.67M | +441.1% | +8.6% | 97.3% |
| Mar 2026 | $275.35M | +27.6% | +40.8% | 67.0% | |
| Mar 2026 | $132.11M | +69.3% | -29.9% | 75.4% | |
| Mar 2026 | $122.94M | -21.1% | -22.3% | 63.2% | |
| Mar 2026 | $82.45M | +70.3% | +16.9% | 95.0% | |
| Mar 2026 | $69.76M | +16.4% | +18.9% | 94.7% | |
| Mar 2026 | $68.14M | +171.5% | +23.3% | 96.0% | |
| Dec 2025 | $66.79M | -15.1% | -6.8% | 41.2% | |
| Mar 2026 | $47.18M | -22.2% | -14.6% | 37.6% | |
| Mar 2026 | $42.4M | -13.8% | +11.5% | 64.0% | |
| Mar 2026 | $5.95M | -54.8% | -26.7% | 8.5% | |
| Peer median (excluding PROF) | $75.3M | +6.9% | +0.9% | 65.5% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67.06M | 46.52M | 26.21M | 54.91M | 81.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.41M | 6.34M | 7.29M | 7.05M | 9.86M |
| Inventory | 7.4M | 7.94M | 6.99M | 5.8M | 11.28M |
| Other Current Assets | 1.15M | 0 | 0 | 0 | 1.27M |
| Total Current Assets | 77.02M | 62.02M | 41.9M | 69.07M | 104.21M |
| Property, Plant & Equipment (Net) | 1.9M | 1.72M | 1.57M | 821.01K | 225K |
| Goodwill | 2.69M | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.43M | 680K | 490K | 261K | 138K |
| Long-term Investments | 3.62M | 0 | 0 | 0 | 410.89K |
| Tax Assets | 0 | 0 | 0 | 87K | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 87.96M |
| Total Non-current Assets | 9.64M | 2.4M | 2.06M | 1.17M | 88.73M |
| Total Assets | 86.66M | 64.42M | 43.96M | 70.23M | 192.94M |
| Account Payables | 3.18M | 2.03M | 865K | 1.32M | 2.14M |
| Short-term Debt | 249.66K | 523K | 2.1M | 1.74M | 291.73K |
| Tax Payables | 0 | 298K | 0 | 0 | 0 |
| Deferred Revenue | 476.35K | 471K | 721K | 419K | 0 |
| Other Current Liabilities | 247.66K | 621K | 1.42M | 1.03M | 5.83M |
| Total Current Liabilities | 4.15M | 4.19M | 6.37M | 6.57M | 8.32M |
| Long-term Debt | 0 | 6.65M | 5M | 2.92M | 6.16M |
| Deferred Tax Liabilities | 0 | 0 | 59K | 0 | 86.83M |
| Deferred Revenue (Non-current) | 873.82K | 764K | 728K | 49K | 531.42K |
| Other Non-current Liabilities | 0 | 0 | 73K | 71K | 108.2K |
| Total Non-current Liabilities | 2M | 8.23M | 6.36M | 3.25M | 93.63M |
| Total Liabilities | 6.15M | 12.42M | 12.73M | 9.81M | 101.95M |
| Common Stock | 219.28M | 205.83M | 222.21M | 281.55M | 443.54M |
| Retained Earnings | (160.48M) | (189.36M) | (217.35M) | (245.17M) | (394.1M) |
| Accumulated OCI | 4.74M | 16.84M | 5.57M | 2.74M | 6.88M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 80.51M | 52M | 31.22M | 60.42M | 90.99M |
| Total Debt | 1.38M | 8.23M | 7.87M | 5.12M | 6.45M |
| Net Debt | (65.69M) | (38.29M) | (18.35M) | (49.79M) | (75.34M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.